通过EGF受体激酶抑制剂阻断EGF依赖细胞增殖
1Department of Biological Chemistry, Hebrew University of Jerusalem, Israel.
概括
研究人员开发了新的蛋白质氨酸激酶抑制剂,这些抑制剂向表皮生长因子 (EGF) 受体. 这些强大的抑制剂有效地阻断了EGF受体活性和细胞增殖,显示出作为抗增殖剂的前景.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白氨酸激酶在细胞信号通路中起着至关重要的作用.
- 表皮生长因子 (EGF) 受体信号的调节失调与各种癌症有关.
- 针对特定的激酶域提供了治疗干预的策略.
研究的目的:
- 为了合成和描述蛋白质氨酸激酶的新型低分子量抑制剂.
- 评估这些抑制剂对EGF受体激酶域的选择性和强度.
- 评估最强大的抑制剂对癌细胞的抗增殖作用.
主要方法:
- 一系列低分子量化合物的系统合成.
- 生物化学测试以确定EGF受体和胰岛素受体激酶域的抑制器亲和力.
- 在A431/克隆15细胞中对EGF依赖的自酸化抑制的评估.
- 在EGF刺激和非刺激条件下进行细胞增殖测定.
主要成果:
- 化合物对EGF受体激酶域的亲和力增加了2500倍.
- 与胰岛素受体激酶相比,抑制剂对EGF受体激酶的有效性显著更高 (高达1000倍).
- 最强效的抑制剂有效地阻断了A431/克隆15细胞中依赖EGF的细胞增殖,而不影响基底增殖.
结论:
- 新型低分子量抑制剂选择性地向EGF受体激酶域.
- 这些抑制剂强烈抑制了依赖EGF的细胞增殖.
- 氨酸蛋白激酶抑制剂代表了抗增殖应用的有前途的治疗策略.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
